Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Nygård, M, Hansen, BT, Kjaer, SK, Hortlund, M, Tryggvadóttir, L, Munk, C, Lagheden, C, Sigurdardottir, LG, Campbell, S, Liaw, K-L & Dillner, J 2021, 'Human papillomavirus genotype-specific risks for cervical intraepithelial lesions', Human vaccines & immunotherapeutics, vol. 17, no. 4, pp. 972-981. https://doi.org/10.1080/21645515.2020.1814097

APA

Nygård, M., Hansen, B. T., Kjaer, S. K., Hortlund, M., Tryggvadóttir, L., Munk, C., Lagheden, C., Sigurdardottir, L. G., Campbell, S., Liaw, K-L., & Dillner, J. (2021). Human papillomavirus genotype-specific risks for cervical intraepithelial lesions. Human vaccines & immunotherapeutics, 17(4), 972-981. https://doi.org/10.1080/21645515.2020.1814097

CBE

Nygård M, Hansen BT, Kjaer SK, Hortlund M, Tryggvadóttir L, Munk C, Lagheden C, Sigurdardottir LG, Campbell S, Liaw K-L, Dillner J. 2021. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions. Human vaccines & immunotherapeutics. 17(4):972-981. https://doi.org/10.1080/21645515.2020.1814097

MLA

Vancouver

Author

Nygård, Mari ; Hansen, Bo T ; Kjaer, Susanne K ; Hortlund, Maria ; Tryggvadóttir, Laufey ; Munk, Christian ; Lagheden, Camilla ; Sigurdardottir, Lara G ; Campbell, Suzanne ; Liaw, Kai-Li ; Dillner, Joakim. / Human papillomavirus genotype-specific risks for cervical intraepithelial lesions. In: Human vaccines & immunotherapeutics. 2021 ; Vol. 17, No. 4. pp. 972-981.

Bibtex

@article{2f1397472cda469583514e1e6d314966,
title = "Human papillomavirus genotype-specific risks for cervical intraepithelial lesions",
abstract = "Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18-51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4-5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5-16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5-15.4), with PPV of 8.0% (95% CI: 6.8-9.3) and OR 23.7 (95% CI: 16.0-63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8-9.2) with PPV of 4.4% (95% CI: 3.3-5.7) and OR of 2.9 (95% CI: 2.0-4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1-3.9), and OR 1.5 (95% CI: 1.1-2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits.",
keywords = "Denmark, high-risk HPV, Iceland, liquid-based cytology, low-risk HPV, Norway, population-based prevalence, Sweden",
author = "Mari Nyg{\aa}rd and Hansen, {Bo T} and Kjaer, {Susanne K} and Maria Hortlund and Laufey Tryggvad{\'o}ttir and Christian Munk and Camilla Lagheden and Sigurdardottir, {Lara G} and Suzanne Campbell and Kai-Li Liaw and Joakim Dillner",
year = "2021",
month = apr,
day = "3",
doi = "10.1080/21645515.2020.1814097",
language = "English",
volume = "17",
pages = "972--981",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "4",

}

RIS

TY - JOUR

T1 - Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

AU - Nygård, Mari

AU - Hansen, Bo T

AU - Kjaer, Susanne K

AU - Hortlund, Maria

AU - Tryggvadóttir, Laufey

AU - Munk, Christian

AU - Lagheden, Camilla

AU - Sigurdardottir, Lara G

AU - Campbell, Suzanne

AU - Liaw, Kai-Li

AU - Dillner, Joakim

PY - 2021/4/3

Y1 - 2021/4/3

N2 - Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18-51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4-5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5-16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5-15.4), with PPV of 8.0% (95% CI: 6.8-9.3) and OR 23.7 (95% CI: 16.0-63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8-9.2) with PPV of 4.4% (95% CI: 3.3-5.7) and OR of 2.9 (95% CI: 2.0-4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1-3.9), and OR 1.5 (95% CI: 1.1-2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits.

AB - Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18-51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4-5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5-16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5-15.4), with PPV of 8.0% (95% CI: 6.8-9.3) and OR 23.7 (95% CI: 16.0-63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8-9.2) with PPV of 4.4% (95% CI: 3.3-5.7) and OR of 2.9 (95% CI: 2.0-4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1-3.9), and OR 1.5 (95% CI: 1.1-2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits.

KW - Denmark

KW - high-risk HPV

KW - Iceland

KW - liquid-based cytology

KW - low-risk HPV

KW - Norway

KW - population-based prevalence

KW - Sweden

U2 - 10.1080/21645515.2020.1814097

DO - 10.1080/21645515.2020.1814097

M3 - Journal article

C2 - 32990181

VL - 17

SP - 972

EP - 981

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 4

ER -

ID: 61555505